Market closed
Prices delayed by at least 15 minutes | Prices updated on 30 Apr 2025, 17.33 BST | Print
Hutchmed (China) Limited (HCM)
ORD USD0.10Open
224.00p
Previous close
225.00p
Trade high
230.00p
Volume
6,083
Year high
353.00p
Year low
185.50p
Dividend yield
–
Market capitalisation
£1.97 bn
P/E ratio
75.57
ISIN
KYG4672N1198
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolioof several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Recent trades
| Date | Time | Price | Quantity | Value (£) |
|---|---|---|---|---|
| 30/04/2025 | 04:35:26 | 230 | 1,413 | 3,249.90 |
| 30/04/2025 | 03:54:26 | 223 | 7 | 15.61 |
| 30/04/2025 | 03:37:24 | 223 | 425 | 947.75 |
| 30/04/2025 | 03:20:49 | 223.25 | 898 | 2,004.79 |
| 30/04/2025 | 09:06:14 | 223.92 | 1,339 | 2,998.29 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.